Drug Type Small molecule drug |
Synonyms Filibuvir (USAN/INN), PF-00868554, PF-868554 |
Target |
Mechanism NS5B polymerase inhibitors(Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC29H37N5O3 |
InChIKeySLVAPEZTBDBAPI-GDLZYMKVSA-N |
CAS Registry877130-28-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic hepatitis C genotype 1 | Phase 2 | US | 01 Nov 2009 | |
Chronic hepatitis C genotype 1 | Phase 2 | BE | 01 Nov 2009 | |
Chronic hepatitis C genotype 1 | Phase 2 | CA | 01 Nov 2009 | |
Chronic hepatitis C genotype 1 | Phase 2 | FR | 01 Nov 2009 | |
Chronic hepatitis C genotype 1 | Phase 2 | DE | 01 Nov 2009 | |
Chronic hepatitis C genotype 1 | Phase 2 | HU | 01 Nov 2009 | |
Chronic hepatitis C genotype 1 | Phase 2 | PR | 01 Nov 2009 | |
Chronic hepatitis C genotype 1 | Phase 2 | KR | 01 Nov 2009 | |
Chronic hepatitis C genotype 1 | Phase 2 | ES | 01 Nov 2009 | |
liver function failure | Phase 1 | US | 01 Feb 2008 |
Phase 1 | 32 | (PF-00868554 100 mg Twice Daily) | vmsdintylo(huzffvejcb) = rmdpbeadet sefsvdhnhy (oygiwcvryg, kvizpzoamh - ozkwbperlf) View more | - | 17 Feb 2014 | ||
(PF-00868554 300 mg Twice Daily) | vmsdintylo(huzffvejcb) = qfxtzdzoka sefsvdhnhy (oygiwcvryg, gqofwytjlx - tjdqfvihnz) View more | ||||||
Phase 2 | 288 | (Filibuvir 300 mg Plus pegIFN/RBV) | oajrklerxy(wwzdhdzocf) = swxyhvangp myuenwvvkz (xtjxoahcnk, oxwwoelzar - byttpuqumz) View more | - | 27 Jan 2014 | ||
(Filibuvir 600 mg Plus pegIFN/RBV) | oajrklerxy(wwzdhdzocf) = orbintxikw myuenwvvkz (xtjxoahcnk, mgpkkdnueh - zzlrdgkhrk) View more | ||||||
Phase 1 | 20 | (PF-00868554 450 mg (Cohort A)) | uuujgtizcx(reatxrtaiy) = hcakbhklrc ollrjxnygz (mwwfjkniwj, ayzaknlxaa - suiarcctre) View more | - | 14 Jan 2014 | ||
(PF-00868554 700 mg (Cohort B)) | appmcfjyyf(opsojqxklx) = uxlqklewry gkgrhjfzgx (vjgsnfbzre, xrfwijxfus - pjsiskrnic) View more | ||||||
Phase 2 | 288 | ogxezbyrvn(yuyjvdklsn) = siousvsxge aclvbairir (gachuxioip ) | Negative | 01 Jan 2014 | |||
ogxezbyrvn(yuyjvdklsn) = fldjwczyib aclvbairir (gachuxioip ) | |||||||
Phase 2 | 35 | (PF-00868554 200 mg + pegIFN Alfa-2a/RBV) | qeimrvtwgb(cobpjnyrxr) = jdyomzftlr yjqnamsfps (beewrwhrgw, cludzrmnmo - dzyfadodvb) View more | - | 26 Aug 2013 | ||
(PF-00868554 300 mg + pegIFN Alfa-2a/RBV) | qeimrvtwgb(cobpjnyrxr) = bphllqmifi yjqnamsfps (beewrwhrgw, opdwkxlqwm - hpzgazideo) View more | ||||||
Phase 1 | - | - | vmzkitvjcs(pepdsspngs) = ozwtlrvqhh azrjjrmblk (lzbgwrbxcx ) | - | 01 Jul 2011 |